Abdulrafeh Naqash to Neoplasms
This is a "connection" page, showing publications Abdulrafeh Naqash has written about Neoplasms.
Connection Strength
1.761
-
Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program. J Clin Oncol. 2022 10 10; 40(29):3439-3452.
Score: 0.440
-
Why Are Randomization and Placebos Included in Many Cancer Trials? JAMA Oncol. 2021 07 01; 7(7):1080.
Score: 0.412
-
The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Hum Vaccin Immunother. 2021 07 03; 17(7):1935-1939.
Score: 0.397
-
Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist. 2022 Sep 02; 27(9):778-789.
Score: 0.112
-
Outcomes of Pregnancy During Immunotherapy Treatment for Cancer: Analysis of Clinical Trials Sponsored by the National Cancer Institute. Oncologist. 2021 10; 26(10):e1883-e1886.
Score: 0.105
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
Score: 0.102
-
Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021 03; 9(3).
Score: 0.101
-
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583.
Score: 0.092